SCHEMBL22200802

SCHEMBL22200802

CC(C)n1c(=O)c(-c2ccc(NSc3ccccc3Cl)nc2)nc2cnc(N)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 5/20 0.41
EGFR P00533 1/20 0.35
FGFR1 P11362 1/20 0.35
SRC P12931 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35
CYP1A2 P05177 6/20 0.35
USP2 O75604 5/20 0.35
CASP7 P55210 4/20 0.35
ALDH1A1 P00352 4/20 0.35
HSD17B10 Q99714 5/20 0.33
MEN1 O00255 3/20 0.33
CASP1 P29466 3/20 0.33
KMT2A Q03164 3/20 0.33
HIF1A Q16665 3/20 0.33
PIK3CA P42336 3/20 0.33
HPGD P15428 1/20 0.33
BRCA1 P38398 1/20 0.33
HBB P68871 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200424 0.86 MTOR (0.37) MTOREGFRFGFR1SRCFGFR2
SCHEMBL22200350 0.85 USP2 (0.38) MTOREGFRFGFR1SRCFGFR2
SCHEMBL22200363 0.84 EGFR (0.46) MTOREGFRFGFR1SRCFGFR2
SCHEMBL25035544 0.82 MTOR (0.42) MTORCYP1A2USP2CASP7ALDH1A1
SCHEMBL22200634 0.81 MTOR (0.41) MTORCYP1A2USP2CASP7ALDH1A1
SCHEMBL22200787 0.79 MTOR (0.40) MTORCYP1A2USP2CASP7ALDH1A1
SCHEMBL22200437 0.77 MTOR (0.52) MTORCYP1A2USP2CASP7ALDH1A1
SCHEMBL22200817 0.77 MTOR (0.40) MTORCYP1A2USP2CASP7ALDH1A1
SCHEMBL22200653 0.77 MTOR (0.38) MTORALDH1A1HSD17B10PIK3CAHPGD
SCHEMBL25035488 0.76 ALDH1A1 (0.44) MTORCYP1A2USP2CASP7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed